The global Cardiac Assist Devices Market is witnessing steady expansion, driven by the rising prevalence of cardiovascular diseases and continuous innovation in cardiac support technologies. The market was valued at USD 1.25 billion in 2023 and is projected to reach USD 2.24 billion by 2032, registering a compound annual growth rate (CAGR) of 6.06% during the forecast period from 2024 to 2032.
Cardiovascular diseases remain one of the leading causes of mortality globally, particularly in the United States, where nearly 30% of all deaths are attributed to heart-related conditions, according to public health data. The growing elderly population further amplifies demand, with the population aged 65 and above expected to reach 73 million by 2030, and nearly 50% of older adults affected by heart disease. These demographic and clinical trends are reinforcing the long-term demand for advanced cardiac assist devices (CADs), including ventricular assist devices and total artificial hearts.
Get free Sample Report@ https://www.snsinsider.com/sample-request/4472
Technological advancements are playing a decisive role in market growth. Recent FDA approvals of next-generation cardiac assist devices have contributed to an estimated 20% increase in market expansion, reflecting strong adoption of minimally invasive and high-efficiency solutions. Innovations such as improved biocompatibility, compact device designs, and enhanced durability are expanding the use of CADs across both acute and chronic cardiac care. Additionally, expanded insurance coverage and healthcare reforms have resulted in a 15% increase in Medicare coverage, significantly improving patient access to life-saving cardiac support technologies.
The market is also benefiting from increased awareness and earlier diagnosis of heart diseases. Public health initiatives and improved diagnostic tools have led to a 15% rise in early cardiac assessments and a 20% increase in early-stage heart disease diagnoses over the past five years. As a result, the use of cardiac assist devices among newly diagnosed patients has grown by 18%, supporting better clinical outcomes and long-term disease management.
From a segmentation perspective, implantable cardiac assist devices dominate the market with approximately 70% share, owing to their long-term effectiveness in managing severe heart failure. Transcutaneous devices account for around 30% of the market, favored for their non-invasive nature and use in emergency or temporary cardiac support. By end user, hospitals lead with nearly 70% market share in 2023, supported by advanced infrastructure and specialized surgical capabilities, while ambulatory surgical centers represent a growing 30% share, driven by minimally invasive procedures and outpatient care trends.
Regionally, North America remains the leading market, with the United States holding the largest share due to its advanced healthcare infrastructure, high disease burden, and rapid adoption of innovative cardiac technologies. Canada contributes approximately 15% of the regional market, supported by rising healthcare investments and increased cardiac health awareness. Ongoing integration of artificial intelligence and machine learning into cardiac assist devices is expected to further enhance monitoring accuracy and device performance across the region.
Despite strong growth prospects, the market faces challenges related to high procedural costs and the need for specialized surgical expertise. Only 18% of hospitals globally are equipped with dedicated facilities and trained teams for cardiac assist device implantation, while just 15% possess the full range of advanced technologies required, highlighting the capital-intensive nature of this segment.
Leading companies shaping the competitive landscape include Abbott Laboratories, Abiomed Inc., Medtronic PLC, Berlin Heart GmbH, LivaNova PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, Jarvik Heart, ReliantHeart Inc., and Carmat SA. Recent developments such as Medtronic’s next-generation HeartWare HVAD System, Abiomed’s FDA-approved Impella® CP 5.0, and Boston Scientific’s updated Watchman FLX device underscore the industry’s focus on innovation and patient-centric design.
Other Trending Reports
Patient Engagement Solutions Market
Kidney Function Tests Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
